Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 5/20 | 0.49 |
| ▸ | IKZF2 | Q9UKS7 | 11/20 | 0.48 |
| ▸ | WIZ | O95785 | 1/20 | 0.47 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.47 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.45 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31334749 | 0.93 | CRBN (0.47) | CRBNIKZF2WIZIKZF1PRMT5 | |
| SCHEMBL30273649 | 0.93 | CRBN (0.54) | CRBNIKZF2WIZPRMT5WDR77 | |
| SCHEMBL20046226 | 0.93 | CRBN (0.54) | CRBNIKZF2WIZPRMT5WDR77 | |
| SCHEMBL31334533 | 0.92 | CRBN (0.49) | CRBNIKZF2WIZIKZF1PRMT5 | |
| SCHEMBL31333603 | 0.91 | IKZF2 (0.53) | CRBNIKZF2WIZIKZF1PRMT5 | |
| SCHEMBL22536268 | 0.91 | WIZ (0.53) | CRBNIKZF2WIZIKZF1 | |
| SCHEMBL31334312 | 0.88 | CRBN (0.49) | CRBNIKZF2WIZPRMT5WDR77 | |
| SCHEMBL31333342 | 0.88 | IKZF2 (0.55) | CRBNIKZF2WIZPRMT5WDR77 | |
| SCHEMBL31413474 | 0.88 | CRBN (0.52) | CRBNIKZF2WIZ | |
| SCHEMBL32669075 | 0.88 | CRBN (0.52) | CRBNIKZF2WIZ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| WO-2024233846-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | LARKSPUR BIOSCIENCES, INC. (US) | 2024-11-14 | — | — | WO | disclosed |